• Explore /
  • Poster
  • / Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.

Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.

Abstract Video & Slides Poster

Authors

null

Stephen J. Schuster

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Stephen J. Schuster , Ling-Yuh Huw , Christopher R. Bolen , Sarit E. Assouline , Nancy L. Bartlett , L Elizabeth Budde , Matthew J. Matasar , Hartmut Koeppen , Emily C. Piccione , Deanna Wilson , Michael C. Wei , Shen Yin , Elicia M. Penuel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT02500407

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7526)

DOI

10.1200/JCO.2022.40.16_suppl.7526

Abstract #

7526

Poster Bd #

180

Abstract Disclosures

Similar Posters

First Author: Michelle A. Fanale

First Author: Franck Morschhauser

First Author: Matthew Steven Davids

First Author: Kiyoshi Ando